<DOC>
	<DOC>NCT00291057</DOC>
	<brief_summary>In a previous phase II study, the safety and efficacy of a novel formulation of malathion 0.5% was evaluated in patients 2 years of age and older. Based on the results of that study, this formulation is currently in a phase III study for that population. The current study will use blood markers and clinical evaluations to determine the safety and tolerability of this formulation when used in children 6-24 months of age.</brief_summary>
	<brief_title>Safety and Tolerability of a Novel Malathion Formulation in Infants and Toddlers With Head Lice</brief_title>
	<detailed_description />
	<mesh_term>Parasitic Diseases</mesh_term>
	<mesh_term>Lice Infestations</mesh_term>
	<mesh_term>Malathion</mesh_term>
	<criteria>Confirmed active head lice infestation Parent or guardian must be able to apply treatment Allergy to pediculicides or hair care products Scalp conditions other than head lice Previous head lice treatment within the past 4 weeks Current antibiotic treatment</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Pediculosis</keyword>
	<keyword>Head Lice</keyword>
</DOC>